Business Context and Reporting Period
This Form 8-K, dated July 17, 2026, reports on Organon & Co. (NYSE: OGN) regarding its ongoing merger with Sun Pharmaceutical Industries Limited. The filing serves as a supplemental disclosure to the Definitive Proxy Statement filed on June 17, 2026, in response to litigation challenging the merger. A special meeting of stockholders to vote on the merger is scheduled for July 23, 2026.
Key Financial Metrics and Projections
The filing provides unaudited financial projections and historical data points relevant to the merger valuation:
- Net Debt: $7,530 million as of March 31, 2026.
- Adjusted LTM EBITDA: $1,832 million as of March 31, 2026 (excluding a $6 million one-time benefit).
- Outstanding Shares: Approximately 284.9 million (fully diluted) as of April 24, 2026.
- Projected Revenue (2026E): $6,252 million.
- Projected Adjusted EBITDA (2026E): $1,894 million.
- Projected Unlevered Free Cash Flow (2026E): $1,010 million.
- Estimated Synergies: Approximately $700 million in aggregate cost synergies across commercial, procurement, R&D, and corporate functions.
| Metric | Q2'26E | Q3'26E | Q4'26E | 2026E | 2027E |
|---|---|---|---|---|---|
| Revenue ($ millions) | 1,546 | 1,613 | 1,632 | 6,252 | 6,475 |
| Adjusted EBITDA ($ millions) | 451 | 507 | 522 | 1,894 | 2,018 |
| Unlevered FCF ($ millions) | 118 | 49 | 338 | 1,010 | 714 |
Material Changes and Litigation
On July 6, 2026, a complaint was filed in the Superior Court of New Jersey (Richard Delman v. Robert Essner, et al.) alleging that the Definitive Proxy Statement contained materially incomplete and misleading disclosures. The plaintiff seeks to enjoin the stockholder vote pending a supplemental proxy statement. On July 13, 2026, the plaintiff filed a motion for a preliminary injunction, which remains pending. Organon has voluntarily supplemented the proxy statement to address these allegations without admitting liability, aiming to avoid delays to the merger.
Guidance, Outlook, and Risks
Management Commentary: The Board previously rejected an initial offer of $13.50 per share in January 2026, evaluating other strategic alternatives including a "merger of equals" followed by divestitures. The Board ultimately determined that the Sun Pharma proposal was the most compelling option after considering execution risks associated with other strategies.
Risks and Contingencies: The filing highlights significant risks, including:
- Failure to obtain the minimum stockholder vote required to approve the merger.
- Failure to receive necessary regulatory approvals.
- Potential competing offers or termination of the agreement.
- Costs and uncertainties associated with ongoing litigation.
- Disruption to business operations and retention of key personnel.
Investor Verification Checklist
- Verify the status of the preliminary injunction motion filed on July 13, 2026, and its potential impact on the July 23, 2026, special meeting.
- Review the full Definitive Proxy Statement (filed June 17, 2026) to understand the complete context of the supplemental disclosures regarding synergy estimates and Board deliberations.
- Confirm the final vote count and regulatory approval status post-July 23, 2026.
- Assess the sensitivity of the $700 million synergy estimate to the integration of commercial and R&D functions.
- Monitor for additional lawsuits challenging the merger, as the filing notes other suits may be filed in the future.